<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003649</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066741</org_study_id>
    <secondary_id>E-6597</secondary_id>
    <nct_id>NCT00003649</nct_id>
  </id_info>
  <brief_title>Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed</brief_title>
  <official_title>Phase I Pilot Trial of Adenovirus p53 in Bronchioloalveolar Cell Lung Carcinoma (BAC) Administered by Bronchoalveolar Lavage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Exposing tumor cells to the p53 gene may improve the body's ability to fight&#xD;
      non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who&#xD;
      have non-small cell lung cancer that cannot be surgically removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the safety of multiple endobronchial treatments with adenovirus p53&#xD;
           bronchoalveolar lavage of a single lobe of the lung in patients with bronchoalveolar&#xD;
           cell lung carcinoma.&#xD;
&#xD;
        -  Evaluate expression of the p53 gene and induction of apoptosis in tumor and normal&#xD;
           tissues exposed to the virus in these patients.&#xD;
&#xD;
        -  Evaluate whether transbronchial administration of adenovirus p53 results in improved&#xD;
           local tumor control in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients undergo biopsy and receive adenovirus p53 by bronchoalveolar lavage on days 1 and&#xD;
      15. Patients repeat biopsy on days 3 and 28. If there is evidence of clinical benefit or&#xD;
      response without significant toxicity, patients may receive a maximum of 3 courses. Treatment&#xD;
      beyond 3 courses must be approved by protocol investigator.&#xD;
&#xD;
      Cohorts of 3 patients are treated at escalating dose levels of adenovirus p53. Patients in&#xD;
      each cohort are followed for dose limiting toxicity (DLT) for 2 weeks after completion of one&#xD;
      course before dose escalation proceeds in subsequent cohorts. If 1 of 3 patients at a dose&#xD;
      level experiences dose limiting toxicity (DLT), then 2 additional patients are entered at the&#xD;
      same dose level. If more than 1 of 5 patients experience DLT, the previous dose is the&#xD;
      maximum tolerated dose (MTD). An additional 10 patients are treated at the MTD.&#xD;
&#xD;
      Patients are followed every 3 months for the first 2 years, every 6 months for the next 3&#xD;
      years, and annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: There will be 15 patients accrued into this study over 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1998</start_date>
  <completion_date type="Actual">June 15, 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5CMV-p53 gene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed unresectable non-small cell lung cancer with a growth pattern&#xD;
             allowing access to the majority of tumor cells via the airway (e.g.,&#xD;
             bronchioloalveolar or papillary adenocarcinoma)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Prothrombin time and partial thromboplastin time normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Room air oxygen saturation greater than 90%&#xD;
&#xD;
          -  FEV1 greater than 1.0 L pCO2 less than 50&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic viral, bacterial, or fungal infections requiring treatment&#xD;
&#xD;
          -  No concurrent illness requiring hospitalization or intravenous medication&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Effective contraception required of all fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior adenovirus gene therapy&#xD;
&#xD;
          -  At least 2 weeks since any systemic biologic therapy including prior biologic response&#xD;
             modifiers and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 weeks since any prior systemic chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Recovered from any prior endocrine therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Recovered from any prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since any surgical procedure requiring anesthesia&#xD;
&#xD;
          -  At least 4 weeks since prior surgical resection of lung tissues&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P. Carbone, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K, Worrell J, Thet LA, Johnson DH, Carbone DP. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol. 2008 Sep 1;26(25):4166-71. doi: 10.1200/JCO.2007.15.6927.</citation>
    <PMID>18757331</PMID>
  </results_reference>
  <results_reference>
    <citation>Kubba SV, Adak S, Schiller J, et al.: Phase I trial of adenovirus p53 in bronchioalveolar cell lung carcinoma (BAC) administered by bronchioalveolar lavage. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1904, 2000.</citation>
  </results_reference>
  <verification_date>February 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2003</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

